Security key
03836J201
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)
CUSIP: 03836J201
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Shares outstanding
- 9,144,889
- Total 13F shares
- 1,847,462
- Share change
- -81,398
- Total reported value
- $3,768,839
- Price per share
- $2.04
- Number of holders
- 25
- Value change
- -$165,845
- Number of buys
- 4
- Number of sells
- 7
Report period
Q1 2025
Institutions
25
Top holders
10
APRE full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Aprea Therapeutics, Inc. SEC filings
Aprea Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03836J201
Recent filing periods:
Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Sio Capital Management, LLC |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
276,603
|
$910,024 | — | 31 Dec 2024 | |
| Stonepine Capital Management, LLC |
13F
13D/G
|
Company |
4.3%
from 13D/G
|
149,221
|
$490,937 | — | 31 Dec 2024 | |
| AIGH Capital Management LLC |
13F
|
Company |
5.9%
|
539,300
|
$1,772,724 | — | 31 Dec 2024 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
3%
|
270,000
|
$888,300 | — | 31 Dec 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
2.2%
|
205,760
|
$676,950 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
173,842
|
$570,202 | — | 31 Dec 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.5%
|
137,174
|
$451,302 | — | 31 Dec 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
1.4%
|
127,960
|
$419,709 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.47%
|
42,663
|
$139,959 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.4%
|
36,808
|
$121,098 | — | 31 Dec 2024 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.39%
|
35,328
|
$116,229 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.19%
|
17,064
|
$55,970 | — | 31 Dec 2024 | |
| LPL Financial LLC |
13F
|
Company |
0.18%
|
16,052
|
$52,811 | — | 31 Dec 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.15%
|
13,864
|
$45,613 | — | 31 Dec 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.14%
|
13,011
|
$42,676 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.09%
|
8,504
|
$27,979 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.06%
|
5,935
|
$19,526 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
4,851
|
$15,959 | — | 31 Dec 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
1,478
|
$4,863 | — | 31 Dec 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.01%
|
824
|
$2,703 | — | 31 Dec 2024 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0.01%
|
806
|
$2,652 | — | 31 Dec 2024 | |
| WealthCollab, LLC |
13F
|
Company |
0%
|
158
|
$520 | — | 31 Dec 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
100
|
$329 | — | 31 Dec 2024 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
40
|
$132 | — | 31 Dec 2024 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
24
|
$79 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
11
|
$36 | — | 31 Dec 2024 | |
| Christian S. Schade |
3/4/5
|
Director |
—
mixed-class rows
|
312,846
mixed-class rows
|
$976,345 | — | 28 Jul 2022 | |
| Scott M. Coiante |
3/4/5
|
SVP, Chief Financial Officer |
—
mixed-class rows
|
234,265
mixed-class rows
|
$533,970 | — | 28 Jul 2022 | |
| Eyal C. Attar |
3/4/5
|
SVP, Chief Medical Officer, Director |
—
class O/S missing
|
57,392
|
$211,254 | — | 03 Jun 2022 | |
| Gregory Alan Korbel |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
81,462
mixed-class rows
|
$168,445 | — | 28 Jul 2022 | |
| Lars B. Abrahmsen |
3/4/5
|
SVP, Chief Scientific Officer |
—
mixed-class rows
|
143,700
mixed-class rows
|
$160,855 | — | 10 Mar 2022 | |
| Nadeem Q. Mirza |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
33,650
mixed-class rows
|
$49,062 | — | 01 May 2024 | |
| Fouad Namouni |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 | |
| Michael Aaron Kelly |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 |
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q1 2025
As of 31 Mar 2025,
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,847,462 shares.
The largest 10 holders included
AIGH Capital Management LLC, Sio Capital Management, LLC, SPHERA FUNDS MANAGEMENT LTD., Nantahala Capital Management, LLC, VANGUARD GROUP INC, DAFNA Capital Management LLC, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, LANDSCAPE CAPITAL MANAGEMENT, L.L.C., and CITADEL ADVISORS LLC.
This page lists
25
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
26
Q1 2025 holders
25
Holder diff
-1
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.